Aarti Drugs Ltd
Aarti Drugs Ltd (AARTIDRUGS) last traded at ₹420, a market capitalisation of ₹3,838 crore, on a P/E of 19.9. Over the past 52 weeks the stock has ranged between ₹319 and ₹535. Aarti Drugs Ltd last reported results for the quarter ended Jun 2026, with sales of ₹703 crore and net profit of ₹50 crore. The next scheduled event is an other on 27 Aug 2026. Figures are as of 25 Aug 2026 and are not real time.
Aarti Drugs Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Aarti Drugs Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹703 cr, up 19.0% from ₹591 cr a year earlier. Net profit was ₹50 cr, down 7.4% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 598 | 557 | 677 | 591 | 653 | 602 | 720 | 703 |
| Expenses | 531 | 495 | 583 | 516 | 569 | 547 | 624 | 605 |
| Operating profit | 67 | 62 | 93 | 74 | 84 | 55 | 96 | 98 |
| OPM % | 11% | 11% | 14% | 13% | 13% | 9% | 13% | 14% |
| Other income | 1 | 12 | 2 | 0 | 0 | 1 | 1 | -1 |
| Interest | 9 | 9 | 9 | 9 | 8 | 9 | 8 | 9 |
| Depreciation | 14 | 14 | 15 | 15 | 16 | 18 | 18 | 18 |
| Profit before tax | 46 | 51 | 71 | 51 | 60 | 29 | 70 | 69 |
| Tax % | 24% | 27% | 12% | -6% | 25% | -40% | 21% | 28% |
| Net profit | 35 | 37 | 63 | 54 | 45 | 41 | 55 | 50 |
| EPS (₹) | 3.84 | 4.06 | 6.89 | 5.91 | 4.96 | 4.44 | 6.05 | 5.50 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Aarti Drugs Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 2,155 | 2,489 | 2,716 | 2,529 | 2,387 | 2,565 | 2,678 |
| Operating profit | 440 | 333 | 309 | 321 | 290 | 309 | 333 |
| OPM % | 20% | 13% | 11% | 13% | 12% | 12% | 12% |
| Net profit | 280 | 205 | 166 | 172 | 168 | 195 | 191 |
| EPS (₹) | 30.09 | 22.14 | 17.96 | 18.65 | 18.42 | 21.36 | 20.95 |
TTM is the trailing twelve months to the most recent quarter.
Aarti Drugs Ltd growth and returns
- 10 Years
- 8%
- 5 Years
- 4%
- 3 Years
- -2%
- TTM
- 11%
- 10 Years
- 11%
- 5 Years
- -7%
- 3 Years
- 5%
- TTM
- 2%
- 10 Years
- 13%
- 5 Years
- -7%
- 3 Years
- -8%
- 1 Year
- -12%
- 10 Years
- 18%
- 5 Years
- 15%
- 3 Years
- 13%
- Last Year
- 13%
Aarti Drugs Ltd shareholding pattern
Promoters held 54.43% at Jun 2026, down from 55.23% at Jun 2025. FIIs 1.52% and DIIs 10.29%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 55.64% | 55.38% | 55.48% | 55.23% | 54.72% | 55.03% | 55.03% | 54.43% |
| FIIs | 2.50% | 2.28% | 2.25% | 2.26% | 2.68% | 2.15% | 1.57% | 1.52% |
| DIIs | 7.83% | 8.77% | 9.70% | 9.94% | 9.90% | 10.12% | 10.22% | 10.29% |
| Public | 34.01% | 33.58% | 32.57% | 32.58% | 32.70% | 32.71% | 33.19% | 33.76% |
| No. of shareholders | 1,90,281 | 1,76,006 | 1,69,761 | 1,60,260 | 1,52,252 | 1,48,363 | 1,44,946 | 1,43,476 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Aarti Drugs Ltd events
The next scheduled event is an other on 27 Aug 2026.
- OtherApproval of Performance Stock Option Plan 2026
See the full results calendar for every Indian company reporting in the next 30 days.
Aarti Drugs Ltd corporate filings
- Closure of Trading WindowInsider Trading / SASTlow impact
- Aarti Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/08/2026 ,inter alia, to consider and approve 'Aarti Drugs Limited - Performance ....Board Meetinglow impact
Cruxal's analysis: Aarti Drugs Limited has announced a board meeting scheduled for August 27, 2026, to…
Read the full analysis - Intimation of Analyst/ Institutional MeetCompany Updatelow impact
Cruxal's analysis: Aarti Drugs Ltd has filed an intimation regarding an upcoming analyst/institutional…
Read the full analysis - Disclosure under Regulation 30 of SEBI Listing RegulationsCompany Updatelow impact
Cruxal's analysis: Aarti Drugs Ltd has submitted a routine disclosure under Regulation 30 of the SEBI…
Read the full analysis - Q1FY27 Earning call transcriptCompany Updatehigh impact
Cruxal's analysis: Aarti Drugs Limited reported a strong start to FY27 with consolidated revenue of 703.6…
Read the full analysis - Intimation of Analyst /Institutional Investors MeetingCompany Updatelow impact
Cruxal's analysis: Aarti Drugs Ltd has announced an intimation regarding an upcoming Analyst/Institutional…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Aarti Drugs Ltd
Cruxal reads every Aarti Drugs Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.